

- ❖ **Name & Designation** : Dr. DivyaVohora, Associate Professor
- ❖ **Address** : Dept. of Pharmacology, JamiaHamdard  
(Hamdard University), New Delhi-110062
- ❖ **Name of the International Conference/ Seminar/Symposium/ Workshop** : British Pharmacological Society 2014. London, UK, 16-18th December 2014
- ❖ **Title of the abstract accepted** : Reduction of estradiol and not increased dihydrotestosterone by letrozole is responsible for its protective effects against pentylenetetrazole-induced kindling in mice
- ❖ **Venue & Date** : Bangkok, Thailand, 11-13th December 2014.
- ❖ **Money sanctioned** : ₹ 1,00,000/-
- ❖ **Money reimbursed** : ₹ 25,845/-

### Participation Report

The annual meeting of British Pharmacological Society (BPS), *Pharmacology 2014*, was held from December 16-18<sup>th</sup> at Queen Elizabeth II Conference Center at London, UK. Over 450 delegates from 37 countries participated and presented their research work in the meeting. These included veterans and experts from academia and pharmaceutical industry as also young enthusiastic researchers and students. There were 12 specialized symposia dedicated to various fields of pharmacology, a training session on clinical pharmacology, 5 plenary/ prize sessions and about 43 oral and 463 poster presentations.

*Academic highlights of the training/workshop including major recommendation and the following:*

- i) New Developments Presented at the Conference and ii) New Developments resulting from the Conference**

The scientific content embodied vast multidisciplinary coverage encompassing varied approaches of pharmacology in drug discovery and development. The specialized symposia were dedicated to

recent advances in various fields of pharmacology such as glycinergic transmission, neurological disorders, biologics and personalized medicine, safety aspects of therapeutics, molecular pharmacology of receptor tyrosine kinases, newer approaches to target identification and validation etc. In addition to these, a training session was conducted that covered the aspects of clinical pharmacology including the novel mechanisms and methods for drug discovery, update on regulatory science and clinical trials. This session was chaired by Dr. John Thompson from Cardiff University, UK. Dr. Duncan Richards from Glaxo SmithKline, UK explained how novel mechanisms are changing our approach towards drug discovery and development. Prof. Sir Alasdair Breckenridge, who was also a former chairman of MHRA, UK highlighted the importance of social networking sites in pharmacovigilance and regulatory science.

The symposia on neurological disorders focused on some of the novel targets including inflammation for management of stroke and tau-based therapies for neurodegenerative diseases. The session also covered current targets and approaches for Parkinson's disease including the role of histone deacetylase inhibitors and for Huntington's disease for which currently there are no satisfactory pharmacological treatment available. Some plenary and prize lectures covered important practical issues such as clinical pharmacology in the poisons unit and tips for publishing etc. The coverage of the meeting, thus, was quite comprehensive and extensive.

Exhibitors from scientific societies (ASPET, The Physiological Society), publishers (Elsevier, Wiley) and companies (Astra Zeneca, Actual Analytics etc) exhibited information about their products/ services etc.

**ii) Name of the publication in case your work is recommended for publication**

I will be sending this work for publication in a reputed International journal.

**iii) Major recommendations**

- BPS is an excellent platform to present your research findings, interact with experts from various disciplines and to network with scientists for exchange of scientific knowledge and expertise.
- Extensive coverage of both basic and clinical pharmacology including cutting edge research and current issues of interest through symposia and other lectures.

**8. Participants contribution to the Conference (100 words)**

I presented my research work entitled "*Reduction of estradiol and not increased dihydrotestosterone by letrozole is responsible for its protective effects against pentylenetetrazole-induced kindling in mice*" on 16<sup>th</sup> December between 4:30-6:00pm session. I actively contributed in this session by explaining and discussing my work with other Scientists. The concept of aromatase inhibition as an approach to treat epilepsy was well appreciated and was considered to be novel by experts. Dr. Chazot from UK expressed great interest in the subject and suggested pursuing the same in epileptic patients concomitantly suffering from breast cancer. The opportunity to present and discuss the work with others was indeed a valuable experience

I also attended various symposia and training sessions conducted in the meeting and also participated in the General Body Meeting of BPS as a member of the Society, voted for the constitution of Society and expressed my interest in joining affinity groups of BPS.

recent advances in various fields of pharmacology such as glycinergic transmission, neurological disorders, biologics and personalized medicine, safety aspects of therapeutics, molecular pharmacology of receptor tyrosine kinases, newer approaches to target identification and validation etc. In addition to these, a training session was conducted that covered the aspects of clinical pharmacology including the novel mechanisms and methods for drug discovery, update on regulatory science and clinical trials. This session was chaired by Dr. John Thompson from Cardiff University, UK. Dr. Duncan Richards from Glaxo SmithKline, UK explained how novel mechanisms are changing our approach towards drug discovery and development. Prof. Sir Alasdair Breckenridge, who was also a former chairman of MHRA, UK highlighted the importance of social networking sites in pharmacovigilance and regulatory science.

The symposia on neurological disorders focused on some of the novel targets including inflammation for management of stroke and tau-based therapies for neurodegenerative diseases. The session also covered current targets and approaches for Parkinson's disease including the role of histone deacetylase inhibitors and for Huntington's disease for which currently there are no satisfactory pharmacological treatment available. Some plenary and prize lectures covered important practical issues such as clinical pharmacology in the poisons unit and tips for publishing etc. The coverage of the meeting, thus, was quite comprehensive and extensive.

Exhibitors from scientific societies (ASPET, The Physiological Society), publishers (Elsevier, Wiley) and companies (Astra Zeneca, Actual Analytics etc) exhibited information about their products/ services etc.

**ii) Name of the publication in case your work is recommended for publication**

I will be sending this work for publication in a reputed International journal.

**iii) Major recommendations**

- BPS is an excellent platform to present your research findings, interact with experts from various disciplines and to network with scientists for exchange of scientific knowledge and expertise.
- Extensive coverage of both basic and clinical pharmacology including cutting edge research and current issues of interest through symposia and other lectures.

**8. Participants contribution to the Conference (100 words)**

I presented my research work entitled "*Reduction of estradiol and not increased dihydrotestosterone by letrozole is responsible for its protective effects against pentylenetetrazole-induced kindling in mice*" on 16<sup>th</sup> December between 4:30-6:00pm session. I actively contributed in this session by explaining and discussing my work with other Scientists. The concept of aromatase inhibition as an approach to treat epilepsy was well appreciated and was considered to be novel by experts. Dr. Chazot from UK expressed great interest in the subject and suggested pursuing the same in epileptic patients concomitantly suffering from breast cancer. The opportunity to present and discuss the work with others was indeed a valuable experience

I also attended various symposia and training sessions conducted in the meeting and also participated in the General Body Meeting of BPS as a member of the Society, voted for the constitution of Society and expressed my interest in joining affinity groups of BPS.